Alpha Tau Medical is the lead sponsor of 18 current clinical trials in our Israel, USA, Canada, France, Egypt, Mexico and Italy registers. 15 are recruiting patients now. All registered phases are Not applicable. The drugs named most often in its trials are Keytruda and Pembrolizumab. The most-studied condition is Pancreatic Cancer.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer
NCT05632913 · ClinicalTrials.gov ↗ · Recurrent Lung Cancer, Lung Cancer
|
Not applicable | Recruiting | 2023-07 | Israel |
|
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
NCT04534127 · ClinicalTrials.gov ↗ · Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
|
Not applicable | Recruiting | 2020-12 | Israel |
|
Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
NCT06698458 · Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
|
Not applicable | Recruiting | 2025-06 | USA, Canada, Israel, Egypt |
|
A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients.
NCT06202118 · ClinicalTrials.gov ↗ · Breast Cancer, Recurrent Breast Cancer, Breast Carcinoma
|
Not applicable | Recruiting | 2024-02 | Israel |
|
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
NCT03889899 · ClinicalTrials.gov ↗ · Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
|
Not applicable | Recruiting | 2020-10 | Israel |
|
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
NCT05047094 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma
Drugs: Keytruda, Pembrolizumab |
Not applicable | Recruiting | 2021-11 | Israel |
|
Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer.
NCT06202248 · ClinicalTrials.gov ↗ · Non-metastatic Prostate Cancer, Locally Recurrent Prostate Cancer
|
Not applicable | Recruiting | 2024-03 | Israel |
|
Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors
NCT05781555 · ClinicalTrials.gov ↗ · Malignant Tumor
|
Not applicable | Recruiting | 2023-03 | Israel |
|
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients
NCT06615635 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma, Alpha Radiation, Immunocompromised
|
Not applicable | Recruiting | 2026-01 | USA, Israel |
|
Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety)
NCT05657743 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer
|
Not applicable | Recruiting | 2023-08 | Israel |
|
Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer
NCT06026943 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma
|
Not applicable | Recruiting | 2026-05 | Italy |
|
Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases
NCT05829291 · ClinicalTrials.gov ↗ · Liver Metastases
|
Not applicable | Recruiting | 2023-10 | Canada |
|
Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer
NCT06755359 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Locally Advanced Pancreatic Cancer
|
Not applicable | Recruiting | 2026-03 | France |
|
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
NCT06910306 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma, Recurrent Gliomas
|
Not applicable | Recruiting | 2025-10 | USA |
|
Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
NCT04068155 · ClinicalTrials.gov ↗ · Skin Cancer, Cutaneous Tumor, Cutaneous Metastasis
|
Not applicable | Recruiting | 2022-04 | France |
|
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)
NCT03737734 · ClinicalTrials.gov ↗ · Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
|
Not applicable | Active, closed | 2018-12 | Israel |
|
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma
NCT05323253 · ClinicalTrials.gov ↗ · Recurrent Squamous Cell Carcinoma
|
Not applicable | Active, closed | 2022-09 | USA, Canada, Mexico, Israel |
|
Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer
NCT04002479 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer
|
Not applicable | Active, closed | 2020-10 | Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Israel | 12 | 10 |
| Clinical trials in USA | 4 | 3 |
| Clinical trials in Canada | 4 | 2 |
| Clinical trials in France | 2 | 2 |
| Clinical trials in Egypt | 1 | 1 |
| Clinical trials in Mexico | 1 | 0 |
| Clinical trials in Italy | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Sponsors with the most current trials registered for this condition.
Alpha Tau Medical is the lead sponsor of 18 current trials on ClinicalTrials.gov in our Israel, USA, Canada, France, Egypt, Mexico and Italy registers, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 15 of its 18 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 2 drugs and biologicals as interventions. The most frequent are Keytruda (1) and Pembrolizumab (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.